Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMPFIRE: Ramucirumab in Synovial Sarcoma
NCT04145700Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2020
- Primary completion
- Feb 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of ramucirumab in synovial sarcoma (SS), sponsored by Eli Lilly and Company. Primary endpoint: Progression Free Survival at 6.4 months. Started Mar 2020; status: terminated.
02
Drugs
ramucirumab
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT04145700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04145700.